Abiopharma

New Form 8-K - Incannex Healthcare Inc. Filed: 2025-06-24 AccNo: 0001213900-25-056901 Size: 243 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa

Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization

Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics

OptimizeRx Corporation Appoints CEO Steve Silvestro to Board of Directors

Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch

Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing

UTHR: United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver

New Form DEFA14A - ENZO BIOCHEM INC Filed: 2025-06-24 AccNo: 0001213900-25-056899 Size: 754 KB

New Form 8-K - ENZO BIOCHEM INC Filed: 2025-06-24 AccNo: 0001213900-25-056897 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

InMed’s INM-901 Significantly Reduces Neuroinflammation in Alzheimer’s Disease Ex Vivo Study

New Form 8-K - NEOGENOMICS INC Filed: 2025-06-24 AccNo: 0001077183-25-000145 Size: 260 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 8-K - Revolution Medicines, Inc. Filed: 2025-06-24 AccNo: 0001193125-25-145242 Size: 256 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements …

New Form 8-K - AMARIN CORP PLC\UK Filed: 2025-06-24 AccNo: 0000950170-25-089218 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.05: Cost Associated with Exit or Disposal Activities Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

NeoGenomics Appoints Dr. Marjorie Green to Board of Directors